Literature DB >> 19812115

Hypothalamic stimulation for trigeminal neuralgia in multiple sclerosis patients: efficacy on the paroxysmal ophthalmic pain.

R Cordella1, A Franzini, L La Mantia, C Marras, A Erbetta, G Broggi.   

Abstract

Trigeminal neuralgia is a disorder characterized by paroxysmal pain arising in one or more trigeminal branches; it is commonly reported in multiple sclerosis. In multiple sclerosis patients the ophthalmic branch may be frequently involved and the risks carried by neurosurgical ablative procedures are higher including major adverse effects such as corneal reflex impairment and keratitis. The objective of this works is to assess the role of posterior hypothalamus neuromodulation in the treatment of trigeminal neuralgia in multiple sclerosis patients. Five multiple sclerosis patients suffering from refractory recurrent trigeminal neuralgia involving all three trigeminal branches underwent deep brain stimulation of the posterior hypothalamus. The rationale of this intervention emerges from our earlier success in treating pain patients suffering from trigeminal autonomic cephalalgias. After follow-up periods that ranged from 1 to 4 years after treatment, the paroxysmal pain arising from the first trigeminal branch was controlled, whereas the recurrence of pain in the second and third trigeminal branches necessitated repeated thermorhizotomies to control in pain in two patients after 2 years of follow-up. In conclusion, deep brain stimulation may be considered as an adjunctive procedure for treating refractory paroxysmal pain within the first trigeminal division so as to avoid the complication of corneal reflex impairment that is known to follow ablative procedures.

Entities:  

Mesh:

Year:  2009        PMID: 19812115     DOI: 10.1177/1352458509107018

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases.

Authors:  Angelo Franzini; Roberto Cordella; Giuseppe Messina; Carlo Efisio Marras; Luigi Michele Romito; Alberto Albanese; Michele Rizzi; Nardo Nardocci; Giovanna Zorzi; Edvin Zekaj; Flavio Villani; Massimo Leone; Orsola Gambini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2012-01-24       Impact factor: 3.307

Review 2.  [Therapeutic neuromodulation in primary headaches].

Authors:  A May; T P Jürgens
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

3.  Neuronal activity in vivo enhances functional myelin repair.

Authors:  Fernando C Ortiz; Chloé Habermacher; Mariana Graciarena; Pierre-Yves Houry; Akiko Nishiyama; Brahim Nait Oumesmar; María Cecilia Angulo
Journal:  JCI Insight       Date:  2019-03-21

Review 4.  Deep brain stimulation.

Authors:  X L Chen; Y Y Xiong; G L Xu; X F Liu
Journal:  Interv Neurol       Date:  2013-09

Review 5.  Pain Management in Multiple Sclerosis: a Review of Available Treatment Options.

Authors:  Talal Aboud; Nathaniel M Schuster
Journal:  Curr Treat Options Neurol       Date:  2019-11-27       Impact factor: 3.598

Review 6.  Invasive Therapies in Multiple Sclerosis.

Authors:  Cihat Uzunköprü
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

7.  The posterior hypothalamus exerts opposing effects on nociception via the A7 catecholamine cell group in rats.

Authors:  Y Jeong; J R Moes; M Wagner; J E Holden
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

8.  Posterior hypothalamic modulation of light-evoked trigeminal neural activity and lacrimation.

Authors:  A Katagiri; K Okamoto; R Thompson; D A Bereiter
Journal:  Neuroscience       Date:  2013-04-30       Impact factor: 3.590

9.  Neuromodulation for cephalgias.

Authors:  Serge Y Rasskazoff; Konstantin V Slavin
Journal:  Surg Neurol Int       Date:  2013-04-17

Review 10.  Pain in multiple sclerosis: a systematic review of neuroimaging studies.

Authors:  D Seixas; P Foley; J Palace; D Lima; I Ramos; I Tracey
Journal:  Neuroimage Clin       Date:  2014-07-05       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.